Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (studio neo-adjuvante portio) Italian collaborative study

被引:173
作者
Buda, A
Fossati, R
Colombo, N
Fei, F
Floriani, I
Alletti, DG
Katsaros, D
Landoni, F
Lissoni, A
Malzoni, C
Sartori, E
Scollo, P
Torri, V
Zola, P
Mangioni, C
机构
[1] Univ Milano Bicocca, San Gerardo Hosp, Dept Obstet & Gynecol, Monza, Italy
[2] European Inst Oncol, Ist Ric Farmacol Mario Negri, Milan, Italy
[3] Cervello Hosp, Palermo, Italy
[4] Univ Turin, Dept Obstet & Gynecol, Gynecol Oncol Unit, Turin, Italy
[5] Hosp Mauriziano Hosp Mauriziano Umberto 1, Gynecol Oncol Dept, Turin, Italy
[6] Univ Brescia, Dept Gynecol & Obstet, Brescia, Italy
[7] Clin Malzoni, Avellino, Italy
[8] Cannizzaro Hosp, Catania, Italy
关键词
D O I
10.1200/JCO.2005.04.172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Neoadjuvant chemotherapy may represent an alternative to irradiation in locally advanced squamous cell cervical cancer. Aims of this study were to compare a three-drug (paclitaxel, ifosfamide, and cisplatin [TIP]) with a two-drug (ifosfamide and cisplatin [IP]) regimen and to assess the prognostic value of pathologic response on survival. Patients and Methods Patients (n = 219) were randomly assigned to ifosfamide 5 g/m(2) during 24 hours plus cisplatin 75 mg/m(2), or paclitaxel 175 mg/m(2) plus ifosfamide 5 g/m(2) during 24 hours and cisplatin 75 mg/m(2) every 3 weeks for three courses. Results Grades 3 to 4 neutropenia, anemia, and thrombocytopenia were more frequent with TIP. We recorded four deaths related to toxicity. The optimal pathologic response (OPT) rate (residual disease < 3 mm stromal invasion) was higher with TIP than with IP (48 % v 23 %; odds ratio, 3.22; 95 % Cl, 1.69 to 5.88; P = .0003). At a median follow-up of 43.4 months, 79 women experienced disease progression or died (46 in the IP arm, 33 in the TIP arm). Patients receiving TIP experienced a treatment failure rate 25 % less than those receiving IP, but this difference was not statistically significant (hazard ratio [HR], 0.75-1 95 % Cl, 0.48 to 1.17; P = .20). Sixty-one patients died (37 in the IP arm, 24 in the TIP arm), and the HR of death was in favor of TIP, although not significantly (HR, 0.66; 95 % Cl, 0.39 to 1.10; P = .11). In patients assessable for response (n = 189), the average death rates were higher in the group that did not achieve OPT (HR, 5.88; 95 % Cl, 2.50 to 13.84; P < .0001). Conclusion The TIP regimen is associated with a higher response rate than the IP regimen, without a statistically significant effect on overall survival. OPT was a prognostic factor for survival.
引用
收藏
页码:4137 / 4145
页数:9
相关论文
共 25 条
[1]   Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[2]   FIGO Special Report on Gynecologic Cancer 2000 [J].
Benedet, JL .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2000, 70 (02) :207-208
[3]   Neoadjuvant chemotherapy for locally advanced cervical cancer:: a systematic review and meta-analysis of individual patient data from 21 randomised trials [J].
Benedetti-Panici, P ;
Bermudez, A ;
Blake, P ;
Cárdenas, J ;
Chang, TC ;
Chiara, S ;
Di Paola, G ;
Floquet, A ;
Guthrie, D ;
Kigawa, J ;
Kumar, L ;
Leborgne, F ;
Lodge, N ;
Poole, C ;
Sardi, J ;
Souhami, L ;
Sundfor, K ;
Symonds, P ;
Tattersall, M ;
Greggi, S ;
Guthrie, D ;
Parker, V ;
Parmar, MKB ;
Sardi, J ;
Stewart, LA ;
Tierney, JF .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (17) :2470-2486
[4]   RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
BONOMI, P ;
BLESSING, JA ;
STEHMAN, FB ;
DISAIA, PJ ;
WALTON, L ;
MAJOR, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) :1079-1085
[5]  
COLOMBO N, 1998, P AN M AM SOC CLIN, V17, P352
[6]   LYMPH-NODE METASTASES IN CARCINOMA OF THE CERVIX UTERI - RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND ITS IMPACT ON SURVIVAL [J].
GIAROLI, A ;
SANANES, C ;
SARDI, JE ;
MAYA, AG ;
BASTARDAS, ML ;
SNAIDAS, L ;
RUEDA, NG ;
VIGHI, S ;
DIPAOLA, GR .
GYNECOLOGIC ONCOLOGY, 1990, 39 (01) :34-39
[7]   Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis [J].
Green, JA ;
Kirwan, JM ;
Tierney, JF ;
Symonds, P ;
Fresco, L ;
Collingwood, M ;
Williams, CJ .
LANCET, 2001, 358 (9284) :781-786
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   2-YEAR SURVIVAL - PREOPERATIVE ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF CERVICAL-CANCER STAGE-IB AND STAGE-II WITH BULKY TUMOR [J].
KIM, DS ;
MOON, H ;
KIM, KT ;
HWANG, YY ;
CHO, SH ;
KIM, SR .
GYNECOLOGIC ONCOLOGY, 1989, 33 (02) :225-230
[10]  
LARA PC, 1990, CANCER CHEMOTHER PHA, V26, P36